Immunotherapeutic and molecular targeted antineoplastic agents including checkpoint inhibitors, idelalisib, mTOR inhibitors, and, to a lesser extent, ibrutinib have been associated with drug-related pneumonitis. Here, MTOR is linked to pneumonitis.